8,600,001 Shares in IN8bio, Inc. (NASDAQ:INAB) Purchased by BIOS Capital Management LP

BIOS Capital Management LP acquired a new stake in IN8bio, Inc. (NASDAQ:INAB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 8,600,001 shares of the company’s stock, valued at approximately $2,212,000. IN8bio makes up approximately 2.4% of BIOS Capital Management LP’s investment portfolio, making the stock its 5th biggest holding. BIOS Capital Management LP owned 11.86% of IN8bio as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its position in shares of IN8bio by 296.7% during the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after acquiring an additional 86,696 shares during the period. Geode Capital Management LLC lifted its position in shares of IN8bio by 56.5% during the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after acquiring an additional 185,919 shares during the period. Sigma Planning Corp lifted its position in shares of IN8bio by 42.0% during the 3rd quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock valued at $230,000 after acquiring an additional 251,600 shares during the period. Alyeska Investment Group L.P. lifted its position in shares of IN8bio by 1,064.5% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock valued at $1,302,000 after acquiring an additional 4,628,482 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of IN8bio during the 4th quarter valued at approximately $1,465,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Trading Down 0.4 %

Shares of INAB opened at $0.23 on Monday. The stock has a fifty day moving average of $0.28 and a two-hundred day moving average of $0.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The company has a market capitalization of $18.32 million, a PE ratio of -0.30 and a beta of 0.03. IN8bio, Inc. has a fifty-two week low of $0.21 and a fifty-two week high of $1.74.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. As a group, analysts forecast that IN8bio, Inc. will post -0.56 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright cut their price objective on IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Friday.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.